KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 139 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q3 2023. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $611 | +16.4% | 35,200 | -5.6% | 0.00% | +50.0% |
| Q2 2023 | $525 | -66.5% | 37,300 | -74.4% | 0.00% | 0.0% |
| Q1 2023 | $1,566 | +174.7% | 145,800 | +282.7% | 0.00% | -33.3% |
| Q4 2022 | $570 | -99.8% | 38,100 | +186.5% | 0.00% | +200.0% |
| Q4 2020 | $235,000 | -51.7% | 13,300 | -58.2% | 0.00% | -50.0% |
| Q3 2020 | $487,000 | -18.6% | 31,800 | +35.3% | 0.00% | -33.3% |
| Q2 2020 | $598,000 | +43.4% | 23,500 | -13.0% | 0.00% | +50.0% |
| Q1 2020 | $417,000 | +179.9% | 27,000 | +100.0% | 0.00% | +100.0% |
| Q4 2019 | $149,000 | -34.6% | 13,500 | -50.0% | 0.00% | 0.0% |
| Q3 2019 | $228,000 | +25.3% | 27,000 | +100.0% | 0.00% | 0.0% |
| Q2 2019 | $182,000 | +106.8% | 13,500 | +175.5% | 0.00% | – |
| Q1 2019 | $88,000 | -35.8% | 4,900 | 0.0% | 0.00% | -100.0% |
| Q4 2018 | $137,000 | +185.4% | 4,900 | +157.9% | 0.00% | – |
| Q3 2018 | $48,000 | – | 1,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,374,392 | $36,376,000 | 4.43% |
| Opaleye Management Inc. | 338,000 | $8,778,000 | 1.72% |
| Lion Point Capital, LP | 495,748 | $7,594,000 | 1.67% |
| Fairmount Funds Management LLC | 212,746 | $3,259,000 | 1.38% |
| Vivo Capital, LLC | 1,151,622 | $17,643,000 | 1.02% |
| Spearhead Capital Advisors, LLC | 270,117 | $4,138,000 | 0.79% |
| Integral Health Asset Management, LLC | 120,000 | $1,838,000 | 0.56% |
| Endurant Capital Management LP | 117,480 | $1,800,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,990 | $3,983,000 | 0.39% |
| Ikarian Capital, LLC | 342,998 | $5,254,000 | 0.38% |